A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT06225310
Phase
PHASE1
Sponsor
Oncotherapeutics
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Selinexor
  • Ruxolitinib
  • Methylprednisolone
Locations (sample)
  • West Hollywood, California, United States|34.09001,-118.36174

Key Eligibility Criteria

  • Patients must meet all the following inclusion criteria to be eligible to enroll in this study:
  • 1\. Has a diagnosis of MM based on standard criteria as follows:
  • Myeloma criteria: Must be At least 1 of 2 1. Clonal bone marrow plasma cells \>10% 2. Biopsy-proven bony or extramedullary plasmacytoma
  • Active Myeloma criteria: Active Myeloma criteria: Must Meet At Least ONE of the Following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →